Young Onset Parkinson's Disease Subtypes and Pathogenic Mechanisms
Trial Snapshot
- Phase
- Not Applicable
- Status
- Recruiting
- Sponsor
- NYU Langone Health
- Enrollment
- 250
- Locations
- 1
- Primary Endpoint
- Alpha-Synuclein seeding amplification (SAA) Assay Results
Study Overview
Brief Summary
Young Onset Parkinson's disease (YOPD) refers to a group of patients in which the disease starts earlier in life (before the age of 50 years) and has a profound impact on most of patient's life. Current knowledge regarding the mechanisms leading to development of Parkinson's disease in younger individuals is lacking, but their understanding is crucial for the successful design of therapeutic strategies and stratifying patients for clinical trials. With this research the investigators aim to clarify the contribution of relevant biological processes in patients with Young onset Parkinson's disease to help understanding disease mechanisms and biomarkers.
Detailed Description
With the present project the investigators propose to study clinical and biological data (from peripheral blood and skin punch biopsy) in subjects with Young and Late Onset Parkinson's disease as well as non-affected subjects (controls) to identify characteristic biological traits for each for this groups.
For each participant, the investigators will collect information about demographic data, clinical data related to the symptoms of Parkinson's disease through standard questionnaire, a clinical exam, and standard interview. A blood sample (from a peripheral vein) and skin punch biopsy will be collected to study genetic and biological markers of the disease. The study duration for each participant is of one in-person visit at the study center.
In a subgroup of subjects, biological data from the lumbar puncture will be collected and analyzed as well.
Study Design
- Study Type
- Observational
- Observational Model
- Cohort
- Time Perspective
- Prospective
Eligibility Criteria
- Ages
- 18 Years to — (Adult, Older Adult)
- Sex
- All
- Accepts Healthy Volunteers
- Yes
Inclusion Criteria
- •YOPD cohort:
- •Male or female 18 years or older (inclusive) of any race and ethnicity
- •Diagnosis of Parkinson's disease (PD) confirmed by a movement disorder specialist and with an age of onset of less than or equal to the age of 50 years old
- •Willingness to undergo a skin punch biopsy
- •LOPD cohort:
- •Male or female 18 years or older (inclusive) of any race and ethnicity
- •Diagnosis of PD confirmed by a movement disorder specialist and with an age of onset after the age of 50 years
- •Healthy Control cohort:
- •Male or female 18 years or older (inclusive) of any race and ethnicity
- •Never been diagnosed with PD as reported by medical history and as assessed by study PI
Exclusion Criteria
- •Diagnosis of atypical parkinsonism (i.e. progressive supranuclear palsy, corticobasal degeneration, multiple system atrophy) or secondary parkinsonism (i.e. normal pressure hydrocephalus, drug-induced parkinsonism).
- •Clinical history of autoimmune or chronic inflammatory disorder or exposure to chronic immunosuppressant or immunomodulatory medications.
- •Dermatological conditions that would prevent performing skin punch biopsies
Arms & Interventions
Healthy Controls
Clinical assessment:
- Medical history
- Assessment of motor and non-motor symptoms of PD through standard rating scales
Biological samples:
- Peripheral blood sample for the study of genetic and multi-omics data
- Skin punch biopsy (3mm) for the assessment of the Alpha-Synuclein seeding amplification (SAA) Assay
For a sub-cohort of subjects:
Lumbar puncture for the collection of spinal fluid for the study of biological profiles
Young-Onset Parkinson's Disease (YOPD) Patients
Clinical assessment:
- History of PD
- Medical history
- Assessment of motor and non-motor symptoms of PD through standard rating scales
Biological samples:
- Peripheral blood sample for the study of genetic and multi-omics data
- Skin punch biopsy (3mm) for the assessment of the Alpha-Synuclein seeding amplification (SAA) Assay
For a sub-cohort of subjects:
- Lumbar puncture for the collection of spinal fluid for the study of biological profiles
Late-Onset Parkinson's Disease (LOPD) Patients
Clinical assessment:
- History of PD
- Medical history
- Assessment of motor and non-motor symptoms of PD through standard rating scales
Biological samples:
- Peripheral blood sample for the study of genetic and multi-omics data
- Skin punch biopsy (3mm) for the assessment of the Alpha-Synuclein seeding amplification (SAA) Assay
For a sub-cohort of subjects:
Lumbar puncture for the collection of spinal fluid for the study of biological profiles
Outcomes
Primary Outcomes
Alpha-Synuclein seeding amplification (SAA) Assay Results
Time Frame: Baseline
Proportion of YOPD participants with positive of alpha-synuclein SAA in central (cerebrospinal fluid) peripheral biospecimens (skin biopsy)
Genetic test results
Time Frame: Baseline
Proportion of YOPD participants with positive genetic testing for gene mutations in known PD-associated genes
Differences in clinical profiles
Time Frame: Baseline
Differences of the clinical profiles related to motor and non-motor symptoms of PD in YOPD as measured by standard clinical rating scales
Secondary Outcomes
No secondary outcomes reported